Odyssey Therapeutics, Inc. - 8-K Filing
Odyssey Therapeutics presented completed Phase 2a OD-001 induction results showing strong clinical proof of concept at UEG Week 2026. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $ODTX